

XVIVO Perfusion – Consensus estimates Q1 2026

Estimates compiled by Modular Finance on behalf of XVIVO Perfusion.

Number of contributors: 7 (all of which have been updated or confirmed before the report)

KPI (MSEK, unless otherwise specified)	Q1 2026E
Net sales	232
Organic growth in local currency (%)	16.16
Gross profit	173
EBITDA	53.2
EBIT	35.2
Net profit	27.4
Earnings per share (SEK)	0.88

XVIVO Perfusion's Q1 report will be released on Friday 24 April at 07.30 CEST.